Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.99 HKD
Change Today +0.51 / 6.82%
Volume 1.6B
1093 On Other Exchanges
Symbol
Exchange
Hong Kong
OTC US
Frankfurt
As of 4:01 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

cspc pharmaceutical group lt (1093) Snapshot

Open
$7.37
Previous Close
$7.48
Day High
$8.57
Day Low
$7.37
52 Week High
04/17/15 - $8.57
52 Week Low
07/30/14 - $5.32
Market Cap
47.2B
Average Volume 10 Days
188.3M
EPS TTM
$0.21
Shares Outstanding
5.9B
EX-Date
05/28/15
P/E TM
37.2x
Dividend
$0.10
Dividend Yield
1.00%
Current Stock Chart for CSPC PHARMACEUTICAL GROUP LT (1093)

Related News

No related news articles were found.

cspc pharmaceutical group lt (1093) Related Businessweek News

No Related Businessweek News Found

cspc pharmaceutical group lt (1093) Details

CSPC Pharmaceutical Group Limited, an investment holding company, manufactures and sells pharmaceutical products. It offers finished drugs, including NBP series primarily for the acute ischemic stroke; Oulaining series primarily for the treatment of mild to moderate memory and mental impairment resulting from vascular dementia, senile dementia, and brain trauma; Xuanning principally for hypertension; Duomeisu, a chemotherapy drug; Jinyouli for the prevention of leucopenia and infection induced by chemotherapy; and Ailineng primarily for the treatment of nerve glioma and brain metastases, and adjuvant treatment of malignant pleural and peritoneal effusion. The company also provides generic drugs, antibiotics, vitamin C products, and caffeine and other drugs. In addition, it researches and develops approximately 170 products for therapeutic areas of anti-infective, cardio-cerebrovascular, diabetes, neurology, and oncology. Further, the company offers pharmaceutical research and development services; and sewage treatment services. It has operations primarily in the People’s Republic of China, other Asian regions, the Americas, and Europe. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. The company is based in Wan Chai, Hong Kong and is considered a Red Chip company due to its listing on the Hong Kong Stock Exchange.

10,565 Employees
Last Reported Date: 03/24/15

cspc pharmaceutical group lt (1093) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: $10.8M
Executive Director
Total Annual Compensation: $3.9M
Executive Director
Total Annual Compensation: $760.0K
Executive Director
Total Annual Compensation: $760.0K
Executive Director
Total Annual Compensation: $760.0K
Compensation as of Fiscal Year 2013.

cspc pharmaceutical group lt (1093) Key Developments

CPSC Pharmaceutical Group Limited Proposes Changes to the Articles of Association

CSPC Pharmaceutical Group Limited announced at its annual general meeting to be held on May 26, 2015, will implement the adoption of the new Articles of Association of the company.

CPSC Pharmaceutical Group Limited Announces Audited Consolidated Cash Flow Results for the Year Ended December 31, 2014

CSPC Pharmaceutical Group Limited announced audited consolidated cash flow results for the year ended December 31, 2014. For the year, the company reported net cash flow from operating activities of HKD 1,806,454,000 against HKD 814,863,000 a year ago. Purchase of property, plant and equipment was HKD 806,998,000 against HKD 597,115,000 a year ago. Purchase of intangible assets was HKD 6,539,000 against HKD 17,315,000 a year ago.

CSPC Pharmaceutical Group Limited Recommends Final Dividend for the Year Ended December 31, 2014, Payable on or Around June 15, 2015; Announces Audited Consolidated Financial Results for the Year Ended December 31, 2014

The directors of CSPC Pharmaceutical Group Limited recommend the payment of a final dividend of 10 cents against 8 cents per share in respect of the year ended December 31, 2014. Subject to approval by the shareholders in the forthcoming annual general meeting, the proposed final dividend will be paid on or around June 15, 2015 to shareholders of the company whose names appear on the register of members of the company on June 2, 2015. The company also announced audited consolidated financial results for the year ended December 31, 2014. For the year, the company reported revenue of HKD 10,955,077,000 against HKD 9,949,103,000 a year ago. Operating profit was HKD 1,674,368,000 against HKD 1,179,978,000 a year ago. Profit before tax was HKD 1,621,484,000 against HKD 1,247,624,000 a year ago. Profit for the year attributable to owners of the company was HKD 1,268,446,000 or 21.26 cents per diluted share against HKD 972,751,000 or 16.54 cents per diluted share a year ago. Capital expenditure in relation to the additions of production facilities amounted to HKD 877 million for the current year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1093:HK $7.99 HKD +0.51

1093 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1093.
View Industry Companies
 

Industry Analysis

1093

Industry Average

Valuation 1093 Industry Range
Price/Earnings 37.6x
Price/Sales 4.3x
Price/Book 5.8x
Price/Cash Flow 37.2x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSPC PHARMACEUTICAL GROUP LT, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.